


1 **Figure S1**



2

3 **Figure S1. TCellSI and heatmaps of T cells derived from Healthy Control, MM and CIDP**


4 **patients.** TCellSI algorithm scores quantifying functional T cell states: Regulating, Helper, and

5 Progenitor exhaustion. Heatmaps depicting expression levels of signature genes for selected T cell

6 states: (A) Regulating, (B) Helper and (C) Progenitor exhaustion. Data are presented as mean ± SD.

7 Statistical significance was set at $p < 0.05$.


14 **Figure S2**



15
16 **Figure S2. CIDP-CAR-T cells exhibit comparable cytotoxicity to MM-CAR-T cells upon**
17 **antigen encounter.** MM-CAR-T (n = 5) and CIDP-CAR-T (n = 5) cells were co-cultured with target
18 cells expressing BCMA (U266^{BCMA-Mut-OE}) or CD19 (NALM-6). Secreted (A) TNF- α and (B) IL-2
19 levels in co-culture supernatants of U266^{BCMA-Mut-OE} and NALM-6. Serial rechallenge assays
20 assessed sustained cytotoxic function of MM-CAR-T (n = 5) and CIDP-CAR-T (n = 5) cells. (C)
21 Schematic of sequential co-culture assay with fresh target cells (U266^{BCMA-mut-OE} or NALM-6) added
22 every 24 h for 3 rounds (R1-R3) at E : T ratios of 1:5 and 1:10. (D) Assessment of sustained


cytotoxicity in the third round. CAR-T cells were pre-challenged with unlabeled targets prior to the addition of fluorescently labeled targets in R3 to quantify specific lysis. Degranulation and perforin expression were measured after 4 h of co-culture. Representative flow plots and quantification of (E-F) CD107a⁺ and (G-H) Perforin⁺ cells within CD8⁺ CAR⁺ T cells. Data are presented as mean ± SD. Statistical significance was set at $p < 0.05$.

45 **Figure S3**




46
47 **Figure S3. Heatmap of signature gene expression corresponding to CIDP-CAR-T and MM-**
48 **CAR-T cell states.**

59 **Figure S4**



60
61 **Figure S4. Gating strategy for T cell phenotype analysis. (A)** Flow cytometry gating strategy for
62 determining the proportions of CD3⁺, CD4⁺, and CD8⁺ T cells in PBMCs from different sources.
63 **(B)** Gating strategy for assessing memory phenotypes in T cells from different sources. **(C)** Gating
64 strategy for evaluating exhaustion phenotypes in T cells from different sources.



75

76 **Figure S5. Gating strategy for T cell functional analysis.** (A) Flow cytometry gating strategy for

77 determining the proportions of Granzyme B⁺ and Perforin⁺ CD8⁺ T cells from different sources. (B)


78 Flow cytometry gating strategy for determining the proportions of IFN-γ⁺ and TNF-α⁺ CD8⁺ T cells

79 from different sources.

80

81

82 **Figure S6**



83

84 **Figure S6. Gating strategy for CAR-T cell phenotype analysis. (A)** Flow cytometry gating

85 strategy for determining the proportions of CD4⁺ and CD8⁺ T cells in CAR-T from different sources.

86 **(B)** Gating strategy for assessing memory phenotypes in CAR-T cells from different sources. **(C)**

87 Gating strategy for evaluating exhaustion phenotypes in CAR-T cells from different sources.


88

89

90

91

92 **Figure S7**



93

94 **Figure S7. Gating strategy for CAR-T cell activation and cytotoxic function. (A)** Flow

95 cytometry gating strategy for assessing CAR-T cell activation following co-culture with antigen-

96 positive tumor cells. **(B)** Flow cytometry gating strategy for evaluating CAR-T cell cytotoxicity

97 against antigen-positive tumor cells following co-culture.

98

99

100

101

102

Figure S8




Figure S8. Gating strategy for CAR-T cell cytotoxic function. (A) Flow cytometry gating strategy for determining the proportions of CD107a⁺ and Perforin⁺ CD8⁺ CAR-T cells following co-culture with antigen-positive tumor cells. **(B)** Flow cytometry gating strategy for evaluating CAR-T cell cytotoxicity against target cells following multiple rounds of co-culture with antigen-positive tumor cells.